Nuvectis Pharma, Inc. (NVCT)
20.55
-1.37
(-6.25%)
USD |
NASDAQ |
Oct 05, 12:21
Nuvectis Pharma 1 Year Total Returns (Daily) : 261.1% for Oct. 2, 2026
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| October 02, 2026 | 261.1% |
| October 01, 2026 | 241.9% |
| September 30, 2026 | 250.8% |
| September 29, 2026 | 246.8% |
| September 28, 2026 | 242.3% |
| September 25, 2026 | 239.8% |
| September 24, 2026 | 263.5% |
| September 23, 2026 | 251.2% |
| September 22, 2026 | 257.7% |
| September 21, 2026 | 250.6% |
| September 18, 2026 | 243.8% |
| September 17, 2026 | 245.4% |
| September 16, 2026 | 252.2% |
| September 15, 2026 | 254.1% |
| September 14, 2026 | 279.1% |
| September 11, 2026 | 268.5% |
| September 10, 2026 | 258.1% |
| September 09, 2026 | 259.3% |
| September 08, 2026 | 274.8% |
| September 04, 2026 | 275.6% |
| September 03, 2026 | 283.8% |
| September 02, 2026 | 274.9% |
| September 01, 2026 | 251.5% |
| August 31, 2026 | 246.5% |
| August 28, 2026 | 263.4% |
| Date | Value |
|---|---|
| August 27, 2026 | 278.8% |
| August 26, 2026 | 265.0% |
| August 25, 2026 | 298.9% |
| August 24, 2026 | 247.5% |
| August 21, 2026 | 271.6% |
| August 20, 2026 | 257.0% |
| August 19, 2026 | 280.0% |
| August 18, 2026 | 224.2% |
| August 17, 2026 | 196.7% |
| August 14, 2026 | 194.9% |
| August 13, 2026 | 201.9% |
| August 12, 2026 | 186.5% |
| August 11, 2026 | 216.6% |
| August 10, 2026 | 214.6% |
| August 07, 2026 | 207.1% |
| August 06, 2026 | 191.5% |
| August 05, 2026 | 179.1% |
| August 04, 2026 | 175.7% |
| August 03, 2026 | 217.6% |
| July 31, 2026 | 209.2% |
| July 30, 2026 | 201.5% |
| July 29, 2026 | 173.7% |
| July 28, 2026 | 160.8% |
| July 27, 2026 | 151.2% |
| July 24, 2026 | 149.8% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Opus Genetics, Inc. | 154.4% |
| Faeth Therapeutics, Inc. | 201.6% |
| ACADIA Pharmaceuticals, Inc. | -6.69% |
| Alnylam Pharmaceuticals, Inc. | -52.34% |
| Savara, Inc. | 37.82% |